Can buy wockhart for long term

• Wockhardt Ltd. with a market capitalization Rs 17,934.77 Crs is one of the leading pharmaceutical company in India. The company has manufacturing units in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. More than 50% of the revenues for this company are from Europe.It has wide  market presence in third world nations  such as Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait.It manufactures formulations, bio pharmaceuticals,  nutrition products, vaccines etc.
• Price of this stock fell steeply in the year 2013 after a warning letter Food and Drug Administration of United States of America for identifying significant violations of current good manufacturing practice for finished pharmaceuticals at the Chikalthana and Wiluj facilities. This had a negative impact on the performance of stock in year 2013 till mid 2014.  From there , a study rise in the price of stock witnessed till date with few dips.
• Sales turnover has increased from Rs 1805.27 Cr year ending March 2014 to Rs 1886.55 Cr year ending March 2015. Sales turnover has never been a issue for this company. Reserves increased from Rs 882.13 Cr year ending March 2014 to Rs 1016.50 Cr year ending March 2015. These fundamentals are impressive. But there is a rise in the debt figure of the company from Rs 181.44 Cr year ending  March 2014 to Rs 833.31 cr year ending March 2015 which one of the obvious concern. Net profit of the firm rose from Rs 198.61 Cr year ending march 2014 to Rs 331.82 Cr year ending march 2015. Consolidated figures of the firm are much healthier than the standalone figures which are of least concern.
• “Company’s UK business backed by effective business development efforts achieved consistent strong quarterly performance and grew by 55% (in £ terms 59%) during the quarter. India business of the company continued to grow significantly at 27% with new product launches and focused sales strategies,”according to Wockhart board.
• The company filed 5 ANDA’s with US FDA during the quarter and received 1 approval, a total 73 ANDA’s are pending for approval till date. UK made 1 new filing during the quarter ended 30th June, 2015, according to Wockhart board.
• Coming to technical parameters of the firm, 52 week low was Rs 802.00 and 52 week high was at Rs 2000. Yesterday the stock appreciated by .87 % closed at Rs 1623.95 with Rs 14.05 rise from the previous close.
• Present level seems to be high for buying this stock, but can enter at this level with a target of Rs 2000. Can stay with this stock for long term , but purchase on dips.